Brian Flanagan, MD
Pulmonary Disease · Birmingham, ALNPI 1154524247
Payments from drug & device makers
Across 519 payments — averaging $27.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$6K
- GSK$2K
- AstraZeneca$2K
- CSL Behring$884
- Boehringer Ingelheim$619
- Insmed, Inc.$461
- plus $3K from 31 others
What the payments were for
- Travel & lodging$1661%
- Food & beverage$8,30959%
- Education$5,62640%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 7 | $5,812 |
| GSK | 125 | $1,659 |
| AstraZeneca | 91 | $1,524 |
| CSL Behring | 35 | $884 |
| Boehringer Ingelheim | 42 | $619 |
| Insmed, Inc. | 23 | $461 |
| Grifols USA, LLC | 29 | $436 |
| Electromed, Inc. | 23 | $308 |
| Genentech USA, Inc. | 23 | $308 |
| Actelion Pharmaceuticals US, Inc. | 17 | $269 |
| Merck | 17 | $259 |
| Mylan Specialty L.p. | 15 | $246 |
| Pfizer | 9 | $169 |
| Novartis | 8 | $155 |
| Regeneron Healthcare Solutions, Inc. | 7 | $123 |
| Johnson & Johnson | 6 | $100 |
| Sanofi | 5 | $96 |
| Philips North America LLC | 3 | $70 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $68 |
| Gilead | 3 | $63 |
| Shire North American Group Inc | 3 | $55 |
| Amgen | 2 | $54 |
| Harmony Biosciences LLC | 3 | $49 |
| Eisai Inc. | 3 | $42 |
| United Therapeutics Corporation | 2 | $38 |
| Advanced Respiratory, Inc | 2 | $32 |
| Biofire Diagnostics, LLC | 1 | $27 |
| Teva Pharmaceuticals USA, Inc. | 2 | $24 |
| Mallinckrodt Enterprises LLC | 1 | $20 |
| Olympus America Inc. | 1 | $20 |
| AbbVie | 1 | $19 |
| ANI Pharmaceuticals, Inc. | 1 | $18 |
| Vapotherm Inc | 1 | $17 |
| Pulmonx Corporation | 1 | $16 |
| Jazz Pharmaceuticals Inc. | 1 | $15 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
| Optinose US, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$5,789
How this compares
$14,101 in reported general payments places this provider in the 75th percentile of 215 pulmonary disease providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 1,027 | $741,641 |
| ZemairaAlpha-1-Proteinase Inhibitor | 12 | $271,798 |
| Breo ElliptaFluticasone/Vilanterol | 478 | $219,549 |
| OpsumitMacitentan | 16 | $205,311 |
| NucalaMepolizumab | 51 | $177,943 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 320 | $161,680 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 213 | $151,207 |
| Dupixent PenDupilumab | 40 | $145,110 |
| XolairOmalizumab | 42 | $132,606 |
| FasenraBenralizumab | 20 | $111,837 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 1,381 | $33,196 |
| Spiriva RespimatTiotropium Bromide | 57 | $31,070 |
| EliquisApixaban | 31 | $20,774 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 81 | $19,196 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 36 | $16,810 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Nucala, Anoro Ellipta, Incruse Ellipta | $1,659 | $1,318,3431,925 claims |
| AstraZenecaBreztri Aerosphere, Fasenra, Symbicort | $1,524 | $278,703296 claims |
| CSL BehringZemaira | $884 | $271,79812 claims |
| Actelion Pharmaceuticals US, Inc.Opsumit | $269 | $205,31116 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat, Combivent Respimat | $619 | $57,635112 claims |
| PfizerEliquis | $169 | $20,77431 claims |
| MerckDulera | $259 | $7,34912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 215 pulmonary disease providers in Alabama.
Other pulmonary disease in Birmingham
- Tejaswini KulkarniBirmingham$1.7M
- Bryan GarciaBirmingham$606K
- Veena AntonyBirmingham$327K
- Steven RoweBirmingham$252K
- Derek RussellBirmingham$190K
- Raymond WadeBirmingham$135K
- Joseph Thachuthara-GeorgeBirmingham$126K
- Jennifer TrevorBirmingham$99K
- Peter MorrisBirmingham$94K
- Amanda DenhamBirmingham$45K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.